Prinnovation GmbH

Priavoid Completes Recruitment for Phase II Alzheimer's Drug Trial of PRI-002

- Priavoid GmbH and PRInnovation GmbH successfully completed recruitment for the PRImus-AD Phase II clinical trial, enrolling 304 patients with early-stage Alzheimer's disease across 40 test centers in six European countries. - The innovative drug candidate PRI-002 represents a first-in-class therapy that targets neuronal destruction through a purely physical mechanism, differing fundamentally from antibody-based treatments. - PRI-002 offers significant advantages including oral administration as a capsule and no risk of brain swelling, eliminating the need for regular MRI monitoring required with current antibody therapies. - Study results are expected in the second half of 2026, with plans for a Phase III approval study if results prove positive.